Moomoo AI 已提取核心訊息
Novo Integrated Sciences, Inc. (Novo), a Nevada-based healthcare company, has entered into a securities purchase agreement with RC Consulting Group LLC, issuing a $70 million unsecured 15-year promissory note with a maturity date of April 26, 2038. The note, which was issued at a purchase price of $57 million plus a 1.52% annual yield, is subject to customary events of default, which could lead to an immediate payment obligation of 125% of the outstanding principal plus accrued interest and collection costs. Novo also received a notification from Nasdaq on February 9, 2024, indicating non-compliance with the minimum bid price requirement for continued listing. This non-compliance was considered an event of default under the terms of the securities purchase agreement and the note. However, on February...Show More
Novo Integrated Sciences, Inc. (Novo), a Nevada-based healthcare company, has entered into a securities purchase agreement with RC Consulting Group LLC, issuing a $70 million unsecured 15-year promissory note with a maturity date of April 26, 2038. The note, which was issued at a purchase price of $57 million plus a 1.52% annual yield, is subject to customary events of default, which could lead to an immediate payment obligation of 125% of the outstanding principal plus accrued interest and collection costs. Novo also received a notification from Nasdaq on February 9, 2024, indicating non-compliance with the minimum bid price requirement for continued listing. This non-compliance was considered an event of default under the terms of the securities purchase agreement and the note. However, on February 16, 2024, Novo and the holder entered into a Limited Waiver, exempting the company from the non-compliance determination related to the minimum bid price requirement, but not extending to potential delisting. The waiver does not affect other terms of the agreement, which remain in full force. Novo issued a press release on February 20, 2024, to announce the waiver and emphasize the company's ongoing commitment to providing patient-first health and wellness services through a multidisciplinary approach and technological innovation.
總部位於內華達州的醫療保健公司Novo Integrated Sciences, Inc.（Novo）已與RC Consulting Group LLC簽訂了證券購買協議，發行了7000萬美元的15年期無抵押本票，到期日爲2038年4月26日。該票據的發行價格爲5700萬美元，年收益率爲1.52％，受慣例違約事件的影響，這可能導致立即支付未償本金的125％加上應計利息和收款成本。Novo還於2024年2月9日收到納斯達克的通知，表示未遵守繼續上市的最低出價要求。根據證券購買協議和票據的條款，這種違規行爲被視爲違約事件。但是，在2024年2月16日，Novo和持有人簽訂了有限豁免，免除了該公司與最低出價要求相關的違規決定，但不包括潛在的退市。豁免不影響協議的其他條款，這些條款仍然完全有效。Novo於2024年2月20日發佈新聞稿，宣佈豁免，並強調該公司持續致力於通過多學科方法和技術創新提供患者至上的健康和保健服務。
總部位於內華達州的醫療保健公司Novo Integrated Sciences, Inc.（Novo）已與RC Consulting Group LLC簽訂了證券購買協議，發行了7000萬美元的15年期無抵押本票，到期日爲2038年4月26日。該票據的發行價格爲5700萬美元，年收益率爲1.52％，受慣例違約事件的影響，這可能導致立即支付未償本金的125％加上應計利息和收款成本。Novo還於2024年2月9日收到納斯達克的通知，表示未遵守繼續上市的最低出價要求。根據證券購買協議和票據的條款，這種違規行爲被視爲違約事件。但是，在2024年2月16日，Novo和持有人簽訂了有限豁免，免除了該公司與最低出價要求相關的違規決定，但不包括潛在的退市。豁免不影響協議的其他條款，這些條款仍然完全有效。Novo於2024年2月20日發佈新聞稿，宣佈豁免，並強調該公司持續致力於通過多學科方法和技術創新提供患者至上的健康和保健服務。
有用
沒用